Abstract
Walker cellsin vivo orin vitro are exceptionally sensitive to the monofunctional alkylating agent CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). The basis of the sensitivity is that CB 1954 forms DNA interstrand crosslinks in Walker cells but not in insensitive cells. Crosslink formation is due to the aerobic reduction of CB 1954 to form 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide by the enzyme DT diaphorase. The 4-hydroxylamine can not crosslink DNA directly but requires further activation by a non-enzymatic reaction with a thioester (such as acetyl coenzyme A). As predicted from their measured DT diaphorase activities, a number of rat hepatoma and hepatocyte cell lines are also sensitive to CB 1954. However, no CB 1954-sensitive tumours or cell lines of human origin have been found. This is because the rate of reduction of CB 1954 by the human form of DT diaphorase is much lower than that of the Walker enzyme (ratio of kcat= 6.4). To overcome this intrinsic resistance of human cells towards CB 1954 a number of strategies have been developed. First, analogues have been developed that are more rapidly reduced by the human form of CB 1954. Second, the cytotoxicity of CB 1954 can be potentiated by reduced pyridinium compounds. Third, a CB 1954 activating enzyme can be targeted to human tumours by conjugating it to an antibody (ADEPT). A nitroreductase enzyme has been isolated fromE. coli that can bioactivate CB 1954 much more rapidly than Walker DT diaphorase and is very suitable for ADEPT. Thus CB 1954 may have a role in the therapy of human tumours.
Similar content being viewed by others
References
Workman P, Morgan JE, Talbot K, Wright KA, Donaldson J, Twentyman PR: CB 1954 Revisited II. Toxicity and antitumour activity. Cancer Chemother Pharmacol 16: 9–14, 1986
Ross WCJ, Mitchley BCV: Nucleotoxic and mutagenic nitrogen mustards, epoxides, ethyleneimines and related substances. Ann Rep Br Empire Cancer Campn 42: 70, 1950
Hendry JA, Homer RF, Rose FL, Walpole AL: Cytotoxic agents: III. Derivatives of ethyleneimine. Br J Pharmacol 6: 357–410, 1951
Khan AH, Ross WCJ: Tumour-growth inhibitory nitrophenylaziridines and related compounds: Structure-activity relationships. Chem Biol Interact 1: 27–47, 1969/70
Cobb LM, Connors TA, Elson LA, Khan AH, Mitchley BCV, Ross WCJ, Whisson ME: 2,4-Dinitro-5-ethyleneiminobenzamide (CB1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem Pharmacol 18: 1519–1527, 1969
Connors TA, Melzack DH: Studies on the mechanism of action of 5-aziridinyl-2,4-dinitrobenzamide (CB 1954), a selective inhibitor of the Walker tumour. Int J Cancer 7: 86–92, 1971
Phillips BJ, Ambrose EJ: Cell hybridization study of resistance to alkylating agents. Nature 231: 146–147, 1971
Kavi BR, Bhisey AN, Bapat CV: Effect of standard chemotherapeutic agents on human tumour cell lines ‘in vitro’. Ind J Cancer 12: 295–301, 1975
Bhat AV, Kesava-Rao KV, Bapat CV: Response of human tumours ‘in vitro’ to CB 1954 (5-(aziridinyl-2, 4-nitrobenzamide). Ind J Cancer 14: 132–135, 1977
Cobb LM: Toxicity of the selective antitumor agent 5-aziridino-2, 4-dinitrobenzamide in the rat. Toxicol Appl Pharmacol 17: 231–238, 1970
Sheard CE, Double JA, Berenbaum MC: The sensitivity to chemotherapeutic agents of a rat tumour grown in immunosuppressed mice. Br J Cancer 25: 838–833, 1971
Jarman M, Melzack DH, Ross WCJ: The metabolism of the anti-tumor agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954). Biochem Pharmacol 25: 2475–2478, 1976
Connors TA, Mandel HG, Melzack DH: Studies on the reversal of the selective anti-tumour effect of the aziridinyl derivative CB 1954 by 4-amino-5-imidazolecarboxamide. Int J Cancer 9: 126–132, 1972
Khan AH, Ross WCJ: Tumour-growth inhibitory nitrophenylaziridines and related compounds: Structure-activity relationships. II. Chem Biol Interact 4: 11–22, 1971/72
Workman P, White RAS, Talbot K: CB 1954 Revisited I. Disposition kinetics and metabolism. Cancer Chemother Pharmacol 16: 1–8, 1986
Venitt S: The differential response of resistant and sensitive strains ofEscherichia coli to the cytotoxic effects of 5-aziridino-2, 4-dinitrobenzamide (CB 1954). Chem Biol Interact 3: 177–191, 1971
Mandel HG, Connors TA, Melzack DH, Merai K: Studies on the mechanism of action of 5-aziridinyl-2,4-dinitrobenzamide in tumor cells. Cancer Res 34: 275–280, 1974
Hickman JA, Melzack DH: Protection against the effects of the antitumour agent CB 1954 by certain imidazoles and related compounds. Biochem Pharmacol 24: 1947–1952, 1975
Hickman JA, Melzack DH: Studies on the protection by imidazoles against the cytotoxicity of the antitumour alkylating agents melphalan and CB 1954. Biochem Pharmacol 25: 2489–2491, 1976
Tisdale MJ, Habberfield AD: Selective inhibition of ribonucleotide reductase by the monofunctional alkylating agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954). Biochem Pharmacol 29: 2845–2853, 1980
Tisdale MJ, Phillips BJ: Inhibition of cyclic 3′,5′-nucleotide phosphodiesterase - A possible mechanism of action of bifunctional alkylating agents. Biochem Pharmacol 24: 211–217, 1975
Tisdale MJ, Phillips BJ: Comparative effects of alkylating agents and other anti-tumour agents on the intracellular level of adenosine 3′,5′-monophosphate in Walker carcinoma. Biochem Pharmacol 24: 1271–1276, 1975
Tisdale MJ, Phillips BJ: The effect of alkylating agents on adenosine 3′,5′-monophosphate metabolism in Walker carcinoma. Biochem Pharmacol 25: 1793–1797, 1976
Tisdale MJ, Phillips BJ: Alterations in adenosine 3′,5′-monophosphate-binding protein in Walker carcinoma cells sensitive or resistant to alkylating agents. Biochem Pharmacol 25: 1831–1836, 1976
Tisdale MJ, Phillips BJ: Cyclic nucleotide metabolism in Walker carcinoma cells resistant to alkylating agents. Biochem Pharmacol 27: 947–952, 1978
Walling JM, Stratford IJ, Stevens MA: Chemopotentiation of CB 1954: the importance of postincubations and the possible involvement of poly(ADP-ribosylation). Int J Radiat Oncol Biol Phys 10: 1661–1664, 1984
Stratford IJ, Williamson C, Hoe S, Adams GE: Radiosensitizing and cytotoxic studies with CB 1954(2,4-dinitro-5-aziridinylbenzamide). Radiat Res 88: 502–509, 1981
Walling JM, Stratford IJ, Adams GE: Radiosensitization by the 2,4-dinitro-5-aziridinylbenzamide CB 1954: a structure/activity study. Int J Radiat Biol 52: 31–41, 1987
Tisdale MJ: Alkylating analogues of the tumour inhibitor 5-aziridinyl-2,4-dinitrobenzamide. Chem Biol Interact 3: 95–107, 1971
Roberts JJ, Friedlos F, Knox RJ: CB 1954 (24-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells. Biochem Biophys Res Commun 140: 1073–1078, 1986
Knox RJ, Friedlos F, Jarman M, Roberts JJ: A new cytotoxic, DNA interstrand crosslinking agent, 5′(aziridin-1-yl)-4-hydroxylamino-2-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol 37: 4661–4669, 1988
Venitt S, Crofton-Sleigh C: The toxicity and mutagenicity of the anti-tumour drug 5-aziridino-2,4-dinitrobenzamide (CB 1954) is greatly reduced in a nitroreductase-deficient strain ofE. coli. Mutagenesis 2: 375–381, 1987
Boland MP, Knox RJ, Roberts JJ: The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem Pharmacol 41: 867–875, 1991
Knox RJ, Friedlos F, Sherwood RF, Melton RG, Anlezark GM: The bioactivation of CB 1954. II. A comparison of anEscherichia coli nitroreductase and Walker DT diaphorase. Biochem Pharmacol 44: 2297–2301, 1992
Knox RJ, Friedlos F, Marchbank T, Roberts JJ: Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem Pharmacol 42: 1691–1697, 1991
Knox RJ, Lydall DA, Friedlos F, Basham C, Rawlings CJ, Roberts JJ: The Walker 256 carcinoma: a cell type inherently sensitive only to those difunctional agents that can form DNA interstrand crosslinks. Mutation Res 255: 227–240, 1991
Knox RJ, Lydall DA, Friedlos F, Basham C, Roberts JJ: The effect of monofunctional or difunctional platinum adducts and of various other associated DNA damage on the expression of transfected DNA in a pair of mammalian cell lines sensitive or resistant to difunctional agents. Biochim Biophys Acta 908: 214–223, 1987
Friedlos F, Quinn J, Knox RJ, Roberts JJ: The properties of total adducts and interstrand crosslinks in the DNA of cells treated with CB 1954. Exceptional frequency and stability of the crosslink. Biochem Pharmacol 43: 1249–1254, 1992
Roberts JJ, Friedlos F: Quantitative estimation of cisplatininduced DNA interstrand cross-links and their repair in mammalian cells: Relationship to toxicity. Pharmac Ther 34: 215–246, 1987
Knox RJ, Boland M, Friedlos F, Coles B, Southan C, Roberts JJ: The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol 37: 4671–4677, 1988
Ernster L: DT diaphorase: A historical review. Chemica Scripta 27A: 1–13, 1987
Riley RJ, Workman P: DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 43: 1657–1669, 1992
Friedlos F, Jarman M, Davies LC, Boland MP, Knox RJ: Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD (P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol 44: 25–31, 1992
Roberts JJ, Marchbank T, Kotsaki-Kovatsi VP, Boland MP, Friedlos F, Knox RJ: Caffeine, aminoimidazolecarboxamide and dicoumarol, inhibitors of NAD(P)H dehydrogenase (quinone) (DT diaphorase), prevent both the cytotoxicity and DNA interstrand crosslinking produced by 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB 1954) in Walker cells. Biochem Pharmacol 38: 4137–4143, 1989
Schor NA, Ogawa K, Lee G, Farber E: The use of the D-T diaphorase for the detection of foci of early neoplastic transformation in rat liver. Cancer Letters 5: 167–171, 1978
Pickett CB, Williams JB, Lu AYH, Cameron RG: Regulation of glutathione transferase and DT-diaphorase mRNAs in persistent hepatocyte nodules during chemical hepatocarcinogenesis. Proc Natl Acad Sci 81: 5091–5095, 1984
Beyer RE, Segura-Aguilar JE, Ernster L: The anticancer enzyme DT diaphorase is induced selectively in liver during ascites hepatoma growth. Anticancer Res 8: 233–238, 1988
Martin LF, Patrick SD, Wallin R: DT-diaphorase in morbidly obese patients. Cancer Lett 36: 341–347, 1987
Smith D, Martin LF, Wallin R: Human DT-diaphorase, a potential cancer protecting enzyme. Its purification from abdominal adipose tissue. Cancer Lett 42: 103–112, 1988
Berger MS, Talcott RE, Rosenblum ML, Silva M, Ali-Osman F, Smith MT: Use of quinones in brain-tumor therapy: Preliminary results of preclinical laboratory investigations. J Toxicol Environ Health 16: 713–719, 1985
Beyer RE, Seugra-Aguilar J, Lind C, Castro VM: DT diaphorase activity in various cells in culture with emphasis on induction in ascites hepatoma cells. Chemica Scripta 27A: 145–150, 1987
Schor NA, Cornelisse CJ: Biochemical and quantitative histochemical study of reduced pyridine nucleotide dehydrogenation by human colonic carcinomas. Cancer Res 43: 4850–4855, 1983
Jaiswal AK, McBride OW, Adesnik M, Nebert DW: Human dioxin-inducible cytosolic (NAD(P)H: menadione oxidoreductase: cDNA sequence and localization of gene to chromosome 16. J Biol Chem 263: 13572–13578, 1988
Boland MP: Studies on the bioactivation of 5-(aziridin-1-yl)-2-4-dinitrobenzamide (CB 1954). Ph.D. Thesis, University of London, 1991
Lambert AJ, Friedlos F, Boland MP, Knox RJ: A CB 1954 analogue that is highly cytotoxic in human tumour cell lines (Abstract). Br J Cancer 65 (Suppl. XVI): 59, 1992
Friedlos F, Biggs PJ, Abrahamson JA, Knox RJ: Potentiation of CB 1954 cytotoxicity by reduced pyridine nucleotides in human tumour cells by stimulation of DT diaphorase activity. Biochem Pharmacol 44: 1739–1743, 1992
Friedlos F, Knox RJ: Metabolism of NAD(P)H by blood components: Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system. Biochem Pharmacol 44: 631–635, 1992
Bagshawe KD: Antibody directed enzymes revive anti-cancer prodrugs concept. Br J Cancer 56: 531–532, 1987
Bagshawe KD: Towards generating cytotocix agents at cancer sites. Br J Cancer 60: 275–281, 1989
Bagshawe KD: Antibody-directed enzyme/prodrug therapy (ADEPT). Biochem Soc Transactions 18: 750–751, 1990
Bagshawe KD, Springer CJ, Searle F, Antoniw P, Sharma SK, Melton RG, Sherwood RF: A cytotoxic agent can be generated selectively at cancer sites. Br J Cancer 58: 700–703, 1988
Senter PD, Saulnier MG, Schreiber GJ, Hirschberg DL, Brown JP, Hellstrom I, Hellstrom KE: Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Immunol 85: 4842–4846, 1988
Shepherd TA, Jungheim LN, Meyer DM, Starling JJ: A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody-lactamase conjugate for the treatment of cancer. Bioorg Med Chem Lett 1: 21–26, 1991
Alexander RP, Beeley NRA, O'Driscoll M, O'Neill FP, Millican TA, Pratt AJ, Willenbrock FW: Cephalosporin nitrogen mustard carbamate prodrugs for ‘ADEPT’. Tetrahedron Lett 32: 3269–3272, 1991
Kerr DE, Senter PD, Burnett WV, Hirschberg DL, Hellstrom I, Hellstrom KE: Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol Immunother 31: 202–206, 1990
Hellstrom KE, Senter PD: Activation of prodrugs by targeted enzymes. Eur J Cancer 27: 1342–1343, 1991
Anlezark GM, Melton RG, Sherwood RF, Coles B, Friedlos F, Knox RJ: The bioactivation of CB 1954. I. Purification and properties of a nitroreductase enzyme forEscherichia colia potential enzyme for antibody directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 44: 2289–2295, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Knox, R.J., Friedlos, F. & Boland, M.P. The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Cancer Metast Rev 12, 195–212 (1993). https://doi.org/10.1007/BF00689810
Issue Date:
DOI: https://doi.org/10.1007/BF00689810